Anticoagulation in advanced renal failure: do factor XI/XIa inhibitors represent the long-awaited shift?
- 1Department of Experimental and Clinical Medicine, University of Florence
Abstract
Advanced chronic kidney disease (CKD), particularly stages G4-G5 and dialysis-dependent kidney failure, is one of the most challenging settings for anticoagulant therapy because thrombotic and bleeding risks coexist and often increase in parallel. Conventional anticoagulants, including vitamin K antagonists, direct oral anticoagulants and heparins, have important limitations in this population, owing to altered pharmacokinetics, limited evidence from randomized trials and an intrinsically unstable hemostatic balance. Inhibitors of factor XI (FXI) and activated factor XI (FXIa) have emerged as a novel strategy designed to attenuate thrombus amplification while preserving physiological hemostasis. Advanced CKD provides a particularly attractive clinical model in which to evaluate this concept, since it combines systemic thrombotic risk with uremic bleeding tendency and, in patients undergoing hemodialysis, repeated activation of the contact pathway by the extracorporeal circuit. This narrative review summarizes the hemostatic abnormalities of advanced CKD, discusses the limitations of currently available anticoagulants, reviews the biological rationale for FXI/FXIa inhibition and critically examines the available phase II clinical evidence in patients with advanced renal disease. Although early studies suggest a favorable safety profile and support the biological plausibility of this therapeutic approach, definitive evidence of clinical benefit is still lacking. Dedicated phase III trials will determine whether selective FXI inhibition can truly improve the net clinical benefit of anticoagulation in advanced CKD by dissociating the protection for pathological thrombosis from the impairment of physiological hemostasis.
Related
- Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations
- Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.
- Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma : A case report
- Integration of Immune checkpoint inhibitors within the definitive radiotherapy-based treatment continuum for locally advanced mucosal head and neck squamous cell carcinoma: a scoping review protocol
- CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
BibTeX
@article{prisco2026anticoagulation,
title = {{Anticoagulation in advanced renal failure: do factor XI/XIa inhibitors represent the long-awaited shift?}},
author = {Domenico Prisco and Edoardo Biancalana and Danilo Malandrino and Irene Mattioli},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
doi = {10.4081/btvb.2026.595},
url = {https://doi.org/10.4081/btvb.2026.595},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Anticoagulation in advanced renal failure: do factor XI/XIa inhibitors represent the long-awaited shift?
AU - Domenico Prisco
AU - Edoardo Biancalana
AU - Danilo Malandrino
AU - Irene Mattioli
PY - 2026
DA - 2026/10/23
JO - Bleeding, Thrombosis and Vascular Biology
DO - 10.4081/btvb.2026.595
UR - https://doi.org/10.4081/btvb.2026.595
AB - Advanced chronic kidney disease (CKD), particularly stages G4-G5 and dialysis-dependent kidney failure, is one of the most challenging settings for anticoagulant therapy because thrombotic and bleeding risks coexist and often increase in parallel. Conventional anticoagulants, including vitamin K antagonists, direct oral anticoagulants and heparins, have important limitations in this population, owing to altered pharmacokinetics, limited evidence from randomized trials and an intrinsically unstable hemostatic balance. Inhibitors of factor XI (FXI) and activated factor XI (FXIa) have emerged as a novel strategy designed to attenuate thrombus amplification while preserving physiological hemostasis. Advanced CKD provides a particularly attractive clinical model in which to evaluate this concept, since it combines systemic thrombotic risk with uremic bleeding tendency and, in patients undergoing hemodialysis, repeated activation of the contact pathway by the extracorporeal circuit. This narrative review summarizes the hemostatic abnormalities of advanced CKD, discusses the limitations of currently available anticoagulants, reviews the biological rationale for FXI/FXIa inhibition and critically examines the available phase II clinical evidence in patients with advanced renal disease. Although early studies suggest a favorable safety profile and support the biological plausibility of this therapeutic approach, definitive evidence of clinical benefit is still lacking. Dedicated phase III trials will determine whether selective FXI inhibition can truly improve the net clinical benefit of anticoagulation in advanced CKD by dissociating the protection for pathological thrombosis from the impairment of physiological hemostasis.
SN - 2785-5309
ER -